6 days ago
Symbiotec Pharmalab IPO Draws Strong, Conflicting Subscription Figures
Symbiotec Pharmalab is selling shares to the public in an IPO.
The company wants to raise ₹1,757 crore.
Investors showed strong interest, but two reports gave different subscription figures because they used different times or data updates.
One report said the IPO was subscribed 25.06 times on the afternoon of August 27.
Another said it was subscribed 5.31 times by the end of August 26.
Most of the money from the issue will go to existing shareholders selling their shares.
The company will use part of its new money to repay debt.
The grey market suggested the shares might list above the IPO price, but this estimate may change and does not guarantee a profit.
Symbiotec Pharmalab’s ₹1,757 crore IPO was reported as subscribed 25.06 times by 2:10 pm on August 27, with particularly strong NII demand.
A separate report said the issue was subscribed 5.31 times by the end of August 26, including 5.05 times in retail and 12.18 times among NIIs.
The IPO comprises a ₹150 crore fresh issue and a ₹1,607 crore offer for sale by existing shareholders.
The company plans to use ₹112.5 crore of the fresh proceeds to repay or prepay borrowings, with the balance for general corporate purposes.
Grey market indications of a ₹285–₹287 premium suggested a potential listing near ₹1,273–₹1,275, though GMPs are unofficial and not guaranteed.
- Who
- Symbiotec Pharmalab, its existing shareholders, investors, brokerages, and anchor investors.
- What
- Symbiotec Pharmalab is conducting a ₹1,757 crore IPO comprising a fresh issue and an offer for sale.
- Where
- The shares are scheduled to list on the BSE and NSE.
- When
- The IPO is open from August 24 to August 27, 2026; allotment is expected on August 28 and listing is tentatively scheduled for September 1.
- Why
- The company is raising funds partly to repay borrowings and partly for general corporate purposes, while existing shareholders will receive proceeds from the offer for sale.
Valuation caution
Growth and leadership optimism
Valuation
Valuation caution
Swastika Investmart rated the IPO ‘subscribe’ but said the valuation was high at about 56.8 times P/E, despite being below the multiples of cited peers.
Growth and leadership optimism
BP Equities rated the issue ‘subscribe’ and said the valuation at ₹988 represented a meaningful discount to the peer average relative to the company’s growth and diversification prospects.
Use of IPO proceeds
Valuation caution
Swastika Investmart highlighted that ₹1,607 crore, or most of the issue, is an offer for sale by promoters and private-equity funds, while only ₹150 crore goes to the company.
Growth and leadership optimism
The company said ₹112.5 crore from the fresh issue would be used to repay or prepay borrowings, with the remaining proceeds available for general corporate purposes.
Business prospects
Valuation caution
Swastika Investmart cited FY26 ROE of 11.19% and ROCE of about 11.56% as limited comfort at the proposed valuation and said the issue was more suitable for long-term investors.
Growth and leadership optimism
Brokerages including SBI Securities, Master Capital Services, KC Securities and BP Equities pointed to the company’s steroidal API leadership, backward or vertical integration, regulatory credentials, customer relationships and diversified products.
Key facts
- IPO size
- ₹1,757 crore
- Price band
- ₹938–₹988 per share
- Reported subscription
- 25.06 times by 2:10 pm on August 27 in one report; 5.31 times by the end of August 26 in another report
- Issue structure
- ₹150 crore fresh issue and ₹1,607 crore offer for sale
- Minimum investment
- 15 shares, requiring ₹14,820 at the upper price band
- Debt repayment
- ₹112.5 crore of fresh-issue proceeds is intended for partial or full repayment or prepayment of borrowings
- Grey market premium
- Reported at ₹285–₹287 per share, implying an estimated listing price of approximately ₹1,273–₹1,275
- Anchor book
- ₹526.2 crore raised through the allocation of 53.25 lakh shares to 34 anchor investors
Quotes
Swastika Investmart
Brokerage firm providing an IPO review and investment rating
“At the issue price of Rs. 988, the IPO is valued at 52x FY26 diluted EPS of Rs. 19, representing a meaningful discount to the peer average. Given Symbiotec’s market leadership in steroidal APIs, strong customer relationships, backward integration and potential from emerging businesses, we believe the valuation offers an attractive entry point relative to its growth and diversification prospects. We thus recommend a “SUBSCRIBE” rating to the issue.”
livemint.com
“₹1,607 crore OFS by promoters/PE funds; only ₹150 crore goes to the company. FY26 ROE 11.19% and ROCE ~11.56% offer limited comfort at ~57x P/E. Suitable for long-term investors seeking exposure to specialised, high-barrier steroidal and hormone APIs.”
livemint.com
Sources
Related news
Symbiotec Pharmalabs IPO Opens With 42% Grey-Market Premium
Symbiotec Pharmalab Shares Set for Premium Market Debut
Symbiotec Pharmalab IPO Opens With Analysts Recommending Subscription
Symbiotec Pharmalab IPO Opens With ₹1,757 Crore Offer
Symbiotec Pharmalab Shares Debut Near Issue Price, Recover Later
PVR Inox Buyback: September 3 Last Day to Buy
Augmont Enterprises Rises Despite Gold-Buying Appeal and Market Risks
BSE Shares Fall as New Closing Auction Session Draws Scrutiny
Spice Lounge Food Works Stock Hits Upper Circuit Amid Crash
Indian Stocks Slide as Oil, Conflict and Yields Rise
